XML 13 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Revenues:    
Revenue under collaborative research and development arrangements $ 4,288,586 $ 1,796,857
Revenue under collaborative research and development arrangements with affiliated entity 233,330 137,000
Grants and miscellaneous revenue 5,240,233 6,176,298
Grants and miscellaneous revenue from affiliated entity 614,036 0
Total revenues 10,376,185 8,110,155
Operating expenses:    
Research and development 24,542,504 18,189,160
General and administrative 7,767,589 5,371,613
Total operating expenses 32,310,093 23,560,773
Loss from operations (21,933,908) (15,450,618)
Other income (expense):    
Interest and other income, net 340,341 333,070
Change in fair value of common stock warrants, net 116,477 (406,249)
Gain (loss) on investment in affiliated entity (1,608,817) 7,480,977
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (23,085,907) $ (8,042,820)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders - basic ($ per share) $ (0.31) $ (0.11)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders - diluted ($ per share) $ (0.31) $ (0.11)
Weighted average number of common shares outstanding used in per share calculations - basic (shares) 74,152,609 72,230,411
Weighted average number of common shares outstanding used in per share calculations - diluted (shares) 74,300,884 72,230,411